PRICE T ROWE ASSOCIATES INC 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 1:22 pm Purchase |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 6,645,474 10.300% |
646,218 (+10.77%) |
Filing |
| 2024-02-12 10:07 am Purchase |
2024-01-31 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 5,999,256 10.100% |
658,842 (+12.34%) |
Filing |
| 2024-02-12 10:03 am Purchase |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 5,340,414 9.600% |
961,255 (+21.95%) |
Filing |
| 2023-02-14 12:38 pm Sale |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 4,379,159 8.000% |
-845,527 (-16.18%) |
Filing |
| 2022-07-11 2:10 pm Purchase |
2022-06-30 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 5,224,686 10.100% |
1,674,158 (+47.15%) |
Filing |
| 2022-02-14 2:34 pm Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 3,550,528 6.900% |
3,550,528 (New Position) |
Filing |